Indocyanine green combined with methylene blue versus methylene blue alone for sentinel lymph node biopsy in breast cancer: a retrospective study.
Breast cancer
Indocyanine green (ICG)
Methylene blue (MB)
Sentinel lymph node biopsy (SLNB)
Sentinel lymph nodes (SLNs)
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
17 May 2023
17 May 2023
Historique:
received:
03
02
2023
accepted:
10
05
2023
medline:
19
5
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
epublish
Résumé
Recent studies have shown that near-infrared (NIR) fluorescence imaging using Indocyanine green (ICG) may improve the efficiency of sentinel lymph node biopsy (SLNB). This study aimed to assess the effectiveness of the combination of ICG and methylene blue (MB) in breast cancer patients undergoing SLNB. We evaluated ICG plus MB (ICG + MB) identification effectiveness with MB alone using retrospective analysis. From 2016 to 2020, we collected data on 300 eligible breast cancer patients who got SLNB treatment in our institution by ICG + MB or MB alone. By comparing the distribution of clinicopathological characteristics, the detection rate of sentinel lymph nodes (SLNs) and metastatic SLNs, as well as the total number of SLNs in the two groups, we were able to assess the imaging efficiency. Fluorescence imaging allowed 131 out of 136 patients in the ICG + MB group to find SLNs. ICG + MB group and MB group had detection rates of 98.5% and 91.5% (P = 0.007, χ ICG has high detection effectiveness for SLNs, and when paired with MB, the detection efficiency can be increased even further. Furthermore, the ICG + MB tracing mode does not involve radioisotopes, which has a lot of promise for clinical use and can take the place of conventional standard detection methods.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have shown that near-infrared (NIR) fluorescence imaging using Indocyanine green (ICG) may improve the efficiency of sentinel lymph node biopsy (SLNB). This study aimed to assess the effectiveness of the combination of ICG and methylene blue (MB) in breast cancer patients undergoing SLNB.
PATIENTS AND METHOD
METHODS
We evaluated ICG plus MB (ICG + MB) identification effectiveness with MB alone using retrospective analysis. From 2016 to 2020, we collected data on 300 eligible breast cancer patients who got SLNB treatment in our institution by ICG + MB or MB alone. By comparing the distribution of clinicopathological characteristics, the detection rate of sentinel lymph nodes (SLNs) and metastatic SLNs, as well as the total number of SLNs in the two groups, we were able to assess the imaging efficiency.
RESULTS
RESULTS
Fluorescence imaging allowed 131 out of 136 patients in the ICG + MB group to find SLNs. ICG + MB group and MB group had detection rates of 98.5% and 91.5% (P = 0.007, χ
CONCLUSION
CONCLUSIONS
ICG has high detection effectiveness for SLNs, and when paired with MB, the detection efficiency can be increased even further. Furthermore, the ICG + MB tracing mode does not involve radioisotopes, which has a lot of promise for clinical use and can take the place of conventional standard detection methods.
Identifiants
pubmed: 37198675
doi: 10.1186/s12893-023-02037-z
pii: 10.1186/s12893-023-02037-z
pmc: PMC10189918
doi:
Substances chimiques
Indocyanine Green
IX6J1063HV
Methylene Blue
T42P99266K
Coloring Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133Subventions
Organisme : Basic medical and health science and technology project of Wenzhou Municipal Bureau of Science and Technology
ID : Y2020744
Informations de copyright
© 2023. The Author(s).
Références
Eur J Surg Oncol. 2014 Jun;40(6):786
pubmed: 24657137
Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1932-47
pubmed: 24085499
Clin Nucl Med. 2016 Feb;41(2):126-33
pubmed: 26447368
Asian Pac J Cancer Prev. 2020 May 01;21(5):1187-1195
pubmed: 32458621
Geburtshilfe Frauenheilkd. 2015 Sep;75(9):935-940
pubmed: 26500370
Sci Rep. 2019 May 6;9(1):6943
pubmed: 31061432
Ann Surg Oncol. 2017 Dec;24(Suppl 3):581-582
pubmed: 29079919
Front Oncol. 2022 Feb 09;12:803804
pubmed: 35223482
Asian J Surg. 2020 Dec;43(12):1149-1153
pubmed: 32143963
J Am Coll Surg. 2019 Apr;228(4):672-678
pubmed: 30582975
JCO Glob Oncol. 2020 Jul;6:1225-1231
pubmed: 32749861
Photodiagnosis Photodyn Ther. 2017 Mar;17:208-215
pubmed: 28017834
Chin Med J (Engl). 2021 Jan 11;134(3):318-325
pubmed: 33522727
Int J Nanomedicine. 2018 Oct 23;13:6689-6698
pubmed: 30425483
Arch Gynecol Obstet. 2020 Mar;301(3):729-736
pubmed: 32055954
Breast. 2014 Apr;23(2):159-64
pubmed: 24456968
Clin Breast Cancer. 2018 Aug;18(4):e555-e559
pubmed: 29429940
Int J Clin Oncol. 2017 Feb;22(1):11-17
pubmed: 27864624
Eur Urol. 2020 Dec;78(6):865-872
pubmed: 32950298
Oncol Lett. 2020 Dec;20(6):373
pubmed: 33154771
Ann Surg. 2015 Aug;262(2):243-8
pubmed: 25822674
Sensors (Basel). 2022 Dec 13;22(24):
pubmed: 36560127
Am J Surg. 2020 Sep;220(3):665-676
pubmed: 32115177
Lancet Glob Health. 2019 Sep;7(9):e1166-e1167
pubmed: 31401995
World J Surg Oncol. 2017 Nov 2;15(1):196
pubmed: 29096643
Zhonghua Bing Li Xue Za Zhi. 2017 Aug 8;46(8):525-529
pubmed: 28810291
Adv Anat Pathol. 2014 Nov;21(6):433-42
pubmed: 25299312
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
Ann Surg Oncol. 2011 Sep;18(9):2483-91
pubmed: 21360250
Breast Cancer. 2012 Oct;19(4):343-8
pubmed: 21725656